Swiss Chemicals Stock News

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...

The analysts covering SKAN Group AG ( VTX:SKAN ) delivered a dose of negativity to shareholders today, by making a...

Key Insights Using the 2 Stage Free Cash Flow to Equity, SoftwareOne Holding fair value estimate is CHF13.45...

Sensirion recently held a groundbreaking ceremony for a new 11,000 m² high-tech production facility in Stafa, Switzerland, designed to address capacity constraints and support future advances in cleanroom manufacturing for the semiconductor industry. By also launching the versatile SGM5304 gas meter module and securing additional land for offices, the company is showcasing both long-term operational commitment and innovation in smart metering solutions to meet the evolving needs of global...

Bachem Holding AG announced that Anne-Kathrin Stoller will become its new CEO on January 1, 2026, following the departure of Thomas Meier after over three decades with the company. Stoller's extensive experience across multiple leadership roles at Bachem, including her recent tenure as Chief Operating Officer Americas, positions her as a leader with deep company and industry knowledge. With Stoller set to bring her operational expertise to the CEO position, we'll explore how this leadership...

Julius Bär Gruppe recently received regulatory approval to open a dedicated branch of Bank Julius Baer Europe Ltd. in Lisbon, Portugal, with the new office set to begin serving ultra-high and high-net-worth clients in early 2026. This move underscores Julius Bär's ongoing commitment to expanding its European footprint and supporting clients with an established, locally-based team while maintaining leadership continuity. We'll explore how establishing a regulated presence in Lisbon could...

Galderma Group (SWX:GALD) received FDA approval for Restylane Lyft with Lidocaine, now cleared for chin augmentation in adults. Backed by pivotal trial data, this move further broadens Restylane Lyft’s indications in the US market. See our latest analysis for Galderma Group. Galderma Group’s FDA win added fresh momentum to its already impressive run this year. Recent gains have kept investor attention squarely on the company’s growth story. The stock’s 47.6% year-to-date share price return...

Temenos (SWX:TEMN) has drawn fresh attention after a shift in its recent stock movement. Investors are closely watching how the company’s performance metrics and market sentiment could shape its outlook in the coming months. See our latest analysis for Temenos. Temenos has seen renewed momentum lately, with the share price climbing 14% over the past month and posting a 15% year-to-date gain. While its one-year total shareholder return stands at an impressive 27%, it is still working to...

With its stock down 2.2% over the past three months, it is easy to disregard Lonza Group (VTX:LONN). It is possible...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...

As European markets face pressures from concerns over artificial intelligence stock valuations and major indices like the STOXX Europe 600 experience declines, investors are increasingly looking for stability in dividend stocks. In uncertain times, a good dividend stock is often characterized by its ability to provide consistent yields and financial resilience, making them attractive options for those seeking reliable income amidst fluctuating market conditions.

BELIMO Holding AG's ( VTX:BEAN ) price-to-earnings (or "P/E") ratio of 56.6x might make it look like a strong sell...

Zurich Insurance Group recently reported a Swiss Solvency Test ratio of 257% as of September 30 and achieved record gross written premium growth, with an 8% increase year-over-year in Property & Casualty and an 11% rise in the Life business, both driven by higher product sales and distribution partnerships. An exceptionally strong capital position and robust premium performance across core divisions reflect strengthened operational momentum for Zurich Insurance Group. We'll examine how...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Investors in Adecco Group AG ( VTX:ADEN ) had a good week, as its shares rose 7.9% to close at CHF24.20 following the...

Key Insights Significant insider control over Xlife Sciences implies vested interests in company growth A total of 4...

Even though Novartis AG's ( VTX:NOVN ) recent earnings release was robust, the market didn't seem to notice. Investors...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 19x, you may consider...

Kardex Holding AG ( VTX:KARN ), is not the largest company out there, but it received a lot of attention from a...

Key Insights Komax Holding's estimated fair value is CHF86.57 based on 2 Stage Free Cash Flow to Equity Current share...

Amrize AG recently raised its annual revenue guidance for 2025, now expecting US$11.7 billion to US$12.0 billion, alongside new details of ongoing merger and acquisition interests shared during its third quarter earnings call. The company’s willingness to temporarily increase leverage for the right M&A opportunity highlights a flexible approach to growth even as profit growth remains subdued. We’ll explore how Amrize AG’s improved revenue outlook underscores its investment narrative amidst...

Shareholders might have noticed that Burckhardt Compression Holding AG ( VTX:BCHN ) filed its half-yearly result this...

Wondering if Novartis is still a smart buy, especially as markets search for true value in giant pharma stocks? While shares have climbed 14.5% year-to-date and are up 13.5% over the last year, price swings like the recent 3.1% gain this week and 3.1% dip last month signal shifting investor moods. This volatility comes as Novartis moves ahead with strategic initiatives, including its focus on innovative medicines and ongoing restructuring to sharpen its business. Headlines continue to...